Product Information
CITALOPRAM HBR 40 MG TABLET is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.0414 per EA under NDC 82009010805. Its NADAC has been published 152 times since Nov 8, 2023.
FDA first approved this application on Oct 28, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Quallent Pharmaceuticals Health LLCNDC
82009010805
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CITALOPRAM HYDROBROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077031FDA Approved
10/28/2004
TE Code
AB
On Market Since
8/1/2023
Pharmacological Classes
Price Statistics
The NADAC for CITALOPRAM HBR 40 MG TABLET has been published 152 times since Nov 8, 2023, and over the history we have for it it has declined 8.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0414 per EA |
|---|---|
| All-time high | $0.0465 (Nov 13, 2024) |
| All-time low | $0.0355 (Nov 20, 2024) |
| 52-week high | $0.0464 |
| 52-week low | $0.0414 |
| Median price | $0.0443 |
| Average price | $0.0436 |
| Largest weekly change | -23.6% (Nov 20, 2024) |
| Weeks tracked | 152 |
| Tracking since | Nov 8, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quallent Pharmaceuticals Health LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Citalopram Hydrobromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CITALOPRAM HBR 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CITALOPRAM HBR 40 MG TABLET, manufactured by Quallent Pharmaceuticals Health LLC, is $0.0414 per EA (NDC 82009010805), effective Sep 30, 2026.
How has the price of CITALOPRAM HBR 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for CITALOPRAM HBR 40 MG TABLET has declined 8.1%. It has been tracked across 152 weekly CMS publications since Nov 8, 2023.
What are the highest and lowest recorded NADAC prices for CITALOPRAM HBR 40 MG TABLET?
Since Nov 8, 2023, the NADAC for CITALOPRAM HBR 40 MG TABLET has ranged from a low of $0.0355 (Nov 20, 2024) to a high of $0.0465 (Nov 13, 2024), with a median of $0.0443 per EA.
Are there cheaper alternatives to CITALOPRAM HBR 40 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CITALOPRAM HBR 40 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CITALOPRAM HBR 40 MG TABLET?
CITALOPRAM HBR 40 MG TABLET (NDC 82009010805) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.